Hayden Royal LLC raised its holdings in shares of Novartis AG (NYSE:NVS) by 8.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,406 shares of the company’s stock after buying an additional 182 shares during the period. Hayden Royal LLC’s holdings in Novartis were worth $217,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of NVS. Primecap Management Co. CA boosted its holdings in shares of Novartis by 4.2% during the first quarter. Primecap Management Co. CA now owns 23,857,216 shares of the company’s stock worth $2,293,633,000 after purchasing an additional 969,985 shares during the period. FMR LLC boosted its holdings in shares of Novartis by 23.7% during the first quarter. FMR LLC now owns 8,678,552 shares of the company’s stock worth $834,356,000 after purchasing an additional 1,662,505 shares during the period. Fisher Asset Management LLC boosted its holdings in shares of Novartis by 3.1% during the second quarter. Fisher Asset Management LLC now owns 8,067,235 shares of the company’s stock worth $736,619,000 after purchasing an additional 244,544 shares during the period. Mawer Investment Management Ltd. boosted its holdings in shares of Novartis by 19.2% during the first quarter. Mawer Investment Management Ltd. now owns 5,680,653 shares of the company’s stock worth $546,138,000 after purchasing an additional 916,167 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in shares of Novartis by 5.0% during the second quarter. Janus Henderson Group PLC now owns 3,903,956 shares of the company’s stock worth $356,470,000 after purchasing an additional 186,461 shares during the period. Institutional investors and hedge funds own 11.87% of the company’s stock.

A number of equities analysts have weighed in on NVS shares. Zacks Investment Research downgraded shares of Novartis from a “buy” rating to a “hold” rating and set a $100.00 target price for the company. in a research note on Friday, July 19th. Liberum Capital raised shares of Novartis from a “hold” rating to a “buy” rating in a research report on Thursday, April 25th. Argus raised their target price on shares of Novartis to $105.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. They noted that the move was a valuation call. JPMorgan Chase & Co. restated a “sell” rating on shares of Novartis in a report on Friday, July 5th. Finally, Kepler Capital Markets cut shares of Novartis from a “buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Four investment analysts have rated the stock with a sell rating, five have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $90.63.

Shares of NVS stock traded down $0.35 on Thursday, hitting $88.66. 57,564 shares of the stock traded hands, compared to its average volume of 2,529,997. The stock has a market cap of $202.40 billion, a price-to-earnings ratio of 17.43, a price-to-earnings-growth ratio of 2.07 and a beta of 0.58. Novartis AG has a 52 week low of $71.33 and a 52 week high of $95.00. The business has a 50 day moving average price of $91.33. The company has a current ratio of 0.94, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Thursday, July 18th. The company reported $1.34 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.20 by $0.14. The firm had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $11.45 billion. Novartis had a net margin of 23.27% and a return on equity of 18.55%. The company’s revenue was up 3.7% on a year-over-year basis. During the same period last year, the firm earned $1.29 EPS. Analysts forecast that Novartis AG will post 5.11 earnings per share for the current fiscal year.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.

Featured Article: Futures Contract

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.